HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of “Hold” from Brokerages

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have been given a consensus rating of “Hold” by the six research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $14.8667.

A number of analysts recently weighed in on the company. Morgan Stanley set a $13.60 target price on HUTCHMED in a research report on Thursday, May 28th. Wall Street Zen upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings downgraded shares of HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Bank of America lowered their price objective on shares of HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Finally, The Goldman Sachs Group reduced their target price on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, July 23rd.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of HCM. Goldman Sachs Group Inc. increased its holdings in shares of HUTCHMED by 8.5% in the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock worth $1,413,000 after buying an additional 7,342 shares during the period. Jane Street Group LLC boosted its holdings in HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after acquiring an additional 124,771 shares during the period. Ameriprise Financial Inc. grew its position in HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares during the last quarter. Bank of America Corp DE grew its position in HUTCHMED by 17.3% during the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after acquiring an additional 3,035 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in HUTCHMED by 19.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock worth $377,000 after acquiring an additional 4,116 shares during the last quarter. 8.82% of the stock is owned by institutional investors.

HUTCHMED Stock Performance

HCM opened at $12.63 on Monday. The business’s fifty day simple moving average is $11.30 and its 200 day simple moving average is $12.87. HUTCHMED has a 52 week low of $9.77 and a 52 week high of $18.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.64 and a quick ratio of 5.50.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The firm had revenue of $139.14 million during the quarter, compared to analysts’ expectations of $304.16 million. On average, analysts predict that HUTCHMED will post 0.23 EPS for the current fiscal year.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.